Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline

McGill, Janet B. B.; Agarwal, Rajiv; Anker, Stefan D. D.; Bakris, George L. L.; Filippatos, Gerasimos; Pitt, Bertram; Ruilope, Luis M. M.; Birkenfeld, Andreas L. L.; Caramori, Maria L. L.; Brinker, Meike; Joseph, Amer; Lage, Andrea; Lawatscheck, Robert; Scott, Charlie; Rossing, Peter; FIDELIO-DKD Investigator; FIGARO-DKD Investigator

Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline

Author:

McGill, Janet B. B.; Agarwal, Rajiv; Anker, Stefan D. D.; Bakris, George L. L.; Filippatos, Gerasimos; Pitt, Bertram; Ruilope, Luis M. M.; Birkenfeld, Andreas L. L.; Caramori, Maria L. L.; Brinker, Meike; Joseph, Amer; Lage, Andrea; Lawatscheck, Robert; Scott, Charlie; Rossing, Peter; FIDELIO-DKD Investigator; FIGARO-DKD Investigator

Tübinger Autor(en):

Birkenfeld, Andreas L.

Published in:

Diabetes Obesity & Metabolism (2023), Bd. 25, H. 6, S. 1512-1522

Verlagsangabe:

Wiley

Language:

English

Full text:

http://dx.doi.org/10.1111/dom.14999

ISSN:

1462-8902